Peptide Radiation Therapy Is Safe and Effective for Neuroendocrine Tumors in Asian Patients | Research

The takeaway

Peptide receptor radionuclide therapy (PRRT) achieved 37.9% response rate with 49-month median progression-free survival and acceptable safety in 107 Asian patients with metastatic neuroendocrine tumors.

49 months
median progression-free survival with PRRT in Asian NET patients

What the researchers found

37.9% partial/complete response rate, 49-month median progression-free survival, with 9% grade 3+ hematological toxicity and 4% grade 3/4 hepatobiliary toxicity in 107 Asian NET patients.

Why it matters

This is one of the largest Asian PRRT datasets, addressing the evidence gap for this population. Epidemiological differences in NETs between populations make population-specific efficacy data essential for clinical decision-making.

The numbers in context

Data from an Asian center. Previous evidence primarily from US, Europe, and Australia.

How the study worked

Retrospective analysis of 107 patients with metastatic neuroendocrine tumors who underwent PRRT from January 2012 to March 2019, with response assessment using RECIST 1.1 criteria and qualitative analysis.

Who was studied

Asian patients with metastatic neuroendocrine tumors receiving PRRT

What this study cannot tell us

Retrospective single-center design; heterogeneous tumor types and grades within the cohort; variable number of treatment cycles; liver metastases confounded hepatobiliary toxicity assessment; no randomized comparator.

How to read the evidence

Moderate evidence from a reasonably large retrospective cohort, providing important population-specific data despite the lack of a randomized control group.

When this study was published

Published in 2024 with data from 2012-2019, providing mature follow-up data on PRRT outcomes.

The bigger picture

PRRT represents one of the most targeted forms of peptide-based cancer therapy. Confirming its safety and efficacy in diverse populations is essential as the treatment becomes more widely available globally.

Questions still open

Are there molecular or genetic factors in Asian NET patients that influence PRRT response differently?
What is the optimal number of PRRT cycles for Asian patients?
How does PRRT compare to other treatments like everolimus or sunitinib in this population?

Common questions

What is peptide receptor radionuclide therapy (PRRT)?

PRRT uses small peptides that specifically bind to receptors on neuroendocrine tumor cells. These peptides carry radioactive molecules that deliver targeted radiation directly to the cancer cells, minimizing damage to surrounding healthy tissue.

Does PRRT work as well for Asian patients as it does for Western patients?

Yes — this study's results (37.9% response rate, 49-month progression-free survival) are comparable to Western data, providing reassurance that PRRT is effective across populations despite known epidemiological differences in neuroendocrine tumors.

Read the original research

Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.

Neuroendocrinology, 114(9), 840-847

View on PubMed ↗Publisher’s paper ↗

Citation

Tham, Wei Ying; Huang, Hian Liang; Tai, David Wai Meng; Allen, John C; Hwang, Jacqueline S G; Loh, Lih Ming; Goh, Brian K P; Ong, Simon Y K; Kek, Peng Chin; Tan, Damien M Y; Ng, David C E; Loke, Kelvin S H. (2024). Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.. Neuroendocrinology, 114(9), 840-847. https://doi.org/10.1159/000538523